Claro Advisors’s PTC Therapeutics PTCT Stock Holding History

Claro Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-607	Closed	-$29K	–	747
2018 Q4	$29K	Buy	+607	New	+$21.8K	0.02%	464

Other funds holding PTCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Claro Advisors's PTCT Position: Q1 2019 in Review

Claro Advisors sold out of PTC Therapeutics (PTCT) in Q1 2019, closing a stake of 607 shares — an estimated $29K sold.

Claro Advisors first reported a position in PTCT in Q4 2018 and held it in 1 quarter. The position peaked at $29K in Q4 2018. 174 funds tracked by Wall St. Rank hold PTCT as of Q1 2019.

Claro Advisors reported no remaining PTC Therapeutics position as of Q1 2019 after selling out during the quarter.
Claro Advisors sold 607 PTC Therapeutics shares in Q1 2019, an estimated $29K.
Claro Advisors first reported a position in PTC Therapeutics in Q4 2018 and held it in 1 quarter.
Claro Advisors's PTC Therapeutics position peaked at $29K in Q4 2018.
174 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2019.

Based on Claro Advisors's 13F filing for Q1 2019, filed 10 May 2019.